Ceva is the world’s seventh largest veterinary pharmaceuticals company and one of the leading independent producers.
Ceva is a veterinary pharmaceuticals and vaccine manufacturer that enjoys a particularly strong competitive position (number three worldwide) in the fast growing poultry biology segment.
The key challenge in the operation was shaping its structure, in particular by offering Ceva’s management a more than €100 million equity financing facility that could be quickly and easily drawn down as needed for acquisitions.
When the shareholder structure was reorganised in 2014 and a sovereign wealth fund acquired an equity interest in the company, Sagard reinvested its entire stake and remains a significant shareholder.